Blood test may catch kidney cancer sooner, study hints
NCT ID NCT06917560
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at whether measuring certain autoantibodies in the blood can help diagnose kidney cancer earlier and predict how the disease will progress. Researchers will analyze data from 400 patients to build a predictive model. The goal is to personalize treatment and avoid unnecessary risks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple blood test to detect kidney cancer earlier and guide personalized treatment decisions.
- What could go wrong
- This is a retrospective study analyzing existing data, not a treatment trial. The model may not work as well in real-world settings or different patient groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOANTIBODY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
first hospital affiliated of Fujian medical university
Fuzhou, Fujian, 350005, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged immune attack shrink kidney tumors before surgery?
- Can filtering the blood slow ALS in people with a troubling antibody?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Drug cocktail aims to shrink kidney tumors before surgery and prevent return
- New antibody aims to unlock immune attack on Hard-to-Treat cancers